A share price of iBio Inc [IBIO] is currently trading at $0.99, up 17.39%. An important factor to consider is whether the stock is rising or falling in short-term value. The IBIO shares have gain 22.62% over the last week, with a monthly amount glided 1.27%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
iBio Inc [NASDAQ: IBIO] stock has seen the most recent analyst activity on May 28, 2024, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $5. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on November 29, 2021, and set its price target to $1.50. On January 22, 2021, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $3 on the stock. Alliance Global Partners started tracking the stock assigning a Buy rating and suggested a price target of $2.55 on June 26, 2020.
iBio Inc experienced fluctuations in its stock price throughout the past year between $0.64 and $6.89. Currently, Wall Street analysts expect the stock to reach $3.6 within the next 12 months. iBio Inc [NASDAQ: IBIO] shares were valued at $0.99 at the most recent close of the market. An investor can expect a potential return of 263.64% based on the average IBIO price forecast.
Analyzing the IBIO fundamentals
Gross Profit Margin for this corporation currently stands at 2.98% with Operating Profit Margin at -44.83%, Pretax Profit Margin comes in at -43.89%, and Net Profit Margin reading is -55.98%. To continue investigating profitability, this company’s Return on Assets is posted at -1.1, Equity is -1.3 and Total Capital is -1.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for iBio Inc [NASDAQ:IBIO] is 1.12. On the other hand, the Quick Ratio is 1.12, and the Cash Ratio is 0.92. Considering the valuation of this stock, the price to sales ratio is 42.97, the price to book ratio is 0.87.
Transactions by insiders
Recent insider trading involved Duran Felipe, Chief Financial Officer, that happened on Jan 10 ’25 when 9191.0 shares were purchased., Brenner Martin completed a deal on Jan 10 ’25 to buy 9191.0 shares. Meanwhile, Chief Legal Officer Banjak Marc bought 9191.0 shares on Jan 10 ’25.
